Men who take phosphodiesterase type 5 (PDE5) inhibitors for erectile dysfunction (ED) are not at higher risk for biochemical recurrence of prostate cancer, according to new research.
Men often have “unrealistic expectations” about their sexual function after radical prostatectomy, according to a team of American and Turkish researchers.
After prostate cancer treatment, men who have sex with men (MSM) have sexual concerns that aren’t always addressed by healthcare providers and standard assessment tools, according to researchers from Canada and Australia.
Researchers have found an association between androgen deprivation therapy (ADT) for prostate cancer and increased risk for Alzheimer’s disease, according to a recent study in the Journal of Clinical Oncology.
Pelvic floor muscle training (PFMT) may improve erectile function and climacturia in men who have undergone prostatectomy, according to Belgian researchers.
Based on their review, the researchers estimated post-operative ED rates of 75-80% for most studies. They added that these rates have not fallen over the past 17 years.